ANGIOGENIC FACTORS AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Ewelina Drela, Arleta Kulwas, Wiesław Jundziłł, Barbara Ruszkowska-Ciastek, Barbara Góralczyk, Katarzyna Stankowska, Zofia Ruprecht, Jacek Kubica, Danuta Rość

Department of Pathophysiology,
Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in
Torun, Poland

INTRODUCTION

- Diabetic foot (DF) is a severe complication of poor controlled diabetes, which may result in nonhealing wounds that lead to lower limb amputation. Impaired angiogenesis seems to play an important role in nonhealing ulceration development.
- VEGF-A and FGF-2 coordinate angiogenesis during healing process. In clinical experiments, these factors are also a potent therapeutic agent in patients with chronic diabetic ulcers. EPCs has brought the new insight into angiogenesis and therapy.
- Therefore, the aim of the study was to evaluate the number of EPCs, plasma levels of VEGF-A, sVEGF-R2 and FGF-2 in diabetic patients.

MATERIALS AND METHODS

- Totally, 75 subjects were enrolled: 45 patients with type 2 diabetes (the study group) and 30 healthy volunteers (the control group). The mean age of the patients was 67.1 years in the study group and 63.3 in the controls. The median duration of T2DM was 12.4 years in the test group.
- Patients were divided into 2 groups: 23 with DF (diabetic foot) and 22 without DF.
- VEGF-A, sVEGF-R2 and FGF-2 plasma concentrations were measured by ELISA.
- The number of EPCs was determined by flow cytometry.

RESULTS

Number of circulating EPCs and concentrations of angiogenic factors in the patients with DF, patients without DF and the controls.

Parameter [unit]	Patients with DF Me[Q1;Q3] I n=23	Patients without DF Me[Q1;Q3] II n=22	The control group Me[Q1;Q3] III n=30	P value
VEGF-A [pg/ml]	36,0 [13,74;73,95]	79,16 [29,56;131,55]	15,06 [7,98;27,84]	IvsII p=0,04 IvsIII p=0,01 IIvsIIIp=0,0002
sVEGF-R2 [pg/ml]	8930,5 [8360,0;10356,0]	10099 [8765,2;10841,5]	10738,75 [9670,5;11766,0]	IvsII p=0,2 IvsIII p=0,007 IIvsIII p=0,07
EPCs/µl	0,41 [0,2;1,22]	0,31 [0,1;1,53]	0,41 [0,2;0,92]	IvsII p=0,0581 IvsIII p=0,7 IIvsIII p=0,6
FGF-2 [pg/ml]	6,39 [5,54;8,42]	4,97 [4,45;6,02]	4,92 [4,6;5,44]	IvsII p=0,0002 IvsIIIp=0,000003 IIvsIII p=0,8

CONCLUSIONS

• The study demonstrated that diabetic patients with DF showed decreased VEGF-A and increased FGF-2 levels compared to the patients without DF. It might be associated with impaired angiogenic response.

 This study was supported by grant from National Centre of Science (Poland) based on the decision no. DEC-2011/01/N/NZ5/00293.



endothelial progenitor cells in patients Angiogenic factors and circulating with type 2 diabetes mellitus

Ewelina Drela, Arleta Kulwas, Barbara Góralczyk, Katarzyna Stankowska, Radosław Wieczór, Danuta Rość

Department of Pathophysiology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

Disbetic foot (DF) is a severe complication of poor controlled diabetes, which may result in nonhealing wounds that lead to lower limb amputation. Impaired angiogenesis seems to play an important role in nonhealing ulceration development. VEGF-A and FGF-2 coordinate angiogenesis during healing process. In clinical experiments, these factors are also a potent therapeutic agent in patients with chronic diabeticulcers. EPCs has brought the new insight into angiogenesis and the rapy. Therefore, the aim of the study was to evaluate the number of EPCs, plasma levels of VEGF-A, sVEGF-R2 and FGF-2 in diabetic patients.

Materials and methods

Totally, 75 subjects were enrolled: 45 patients with type 2 diabetes (the study group) and 30 healthy volunteers (the control group). The mean age of the patients was 67.1 years in the study group and 63.3 in the controls. The median during of 712 DM was 12.4 years in the test group. Patients were divided into 2 groups; 23 with DF (diabetic foot) and 22 without DF. VEGF-A2, sVEGF-R2 and FGF-2 plasma concentrations were measured by ELISA. The number of EPCs was determined by flow cytometry.

Results
The results are presented in the table below.

P value	100 May 100 Ma	The state of the s	IvsII p=0,04	IvsIII p=0,01	$\Pi vs \Pi \Pi p = 0,0002$	IvsII p=0,2	IvsIII p=0,007	HvsIII p=0,07	IvsII p=0,0581	IvsⅢ p=0,7	ПvsШ_p=0,6	IvsII p=0,0002	IvsIIIp=0,000003	ПуеЩ п—0 8
The control group	Tu=30 田 n=30		15,06	[7,98;27,84]		10738,75	[9670,5;11766,0]		0,41	[0,2;0,92]		4,92	[4,6;5,44]	
Patients without	Me[Q1;Q3]	II n=22	79,16	[29,56;131,55]		10099	[8765,2;10841,5]		0,31	[0,1;1,53]		4,97	[4,45;6,02]	
Patients with DF	In=23		36,0	[13,74;73,95]		8930,5	[8360,0;10356,0]		0,41	[0,2;1,22]		6,39	[5,54;8,42]	
Parameter			VEGF-A	[lm/gd]		sVEGF-	R2	[lm/gd]	EPCs/µ1			FGF-2	[lm/gd]	
	Patients with DF Patients without The	Patients with DF Patients without Me[Q1;Q3] I n=23 Me[Q1;Q3]	Patients with DF	Patients with DF Patients without The control group Me[Q1;Q3] Me[Q1;Q3] In=23 Me[Q1;Q3] In=20 In=20 T9,16 15,06	Patients with DF	Patients with DF	Patients with DF Patients without The control group	Patients with DF MelQ1;Q31 Patients with but DF MelQ1;Q31 Patients with but DF MelQ1;Q31 The control group MelQ1;Q31 36.0 1 n=23 MelQ1;Q31 II n=30 36.0 19.16 15.06 [13,74;73,95] [29,56;131,55] [7,98;27,84] 8930,5 10099 10738,75 [8360,0;10356,0] [8765,2;10841,5] [9670,5;11766,0] 0,41 0,31 0,41 [0,2;1,22] [0,1;1,53] [0,2;0,92] 6,39 4,97 4,97 (5,54;8,42] [4,45;6,02] [4,65,544]						

Table 1. Number of circulating EPCs and concentrations of angiogenic factors in the patients with DF, patients without DF and the controls.

Conclus ions:

The study demonstrated that diabetic patients with DF showed decreased VEGF-A and increased FGF-2 levels compared to the patients without DF. It might be associated with impaired angiogenic response.